Related Experiment Video
Updated: Jan 20, 2026

Intra-Peritoneal Transplantation for Generating Acute Myeloid Leukemia in Mice
Published on: January 6, 2023
Meningioma 1 is indispensable for mixed lineage leukemia-rearranged acute myeloid leukemia
Amit Sharma1, Nidhi Jyotsana1, Razif Gabdoulline1
1Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.
Abstract:
Mixed lineage leukemia (MLL/KMT2A) rearrangements (MLL-r) are one of the most frequent chromosomal aberrations in acute myeloid leukemia. We evaluated the function of Meningioma 1 (MN1), a co-factor of HOXA9 and MEIS1, in human and murine MLL-rearranged leukemia by CRISPR-Cas9 mediated deletion of MN1. MN1 was required for in vivo leukemogenicity of MLL positive murine and human leukemia cells. Loss of MN1 inhibited cell cycle and proliferation, promoted apoptosis and induced differentiation of MLL-rearranged cells. Expression analysis and chromatin immunoprecipitation with sequencing from previously reported data sets demonstrated that MN1 primarily maintains active transcription of HOXA9 and HOXA10, which are critical downstream genes of MLL, and their target genes like BCL2, MCL1 and Survivin. Treatment of MLL-rearranged primary leukemia cells with anti-MN1 siRNA significantly reduced their clonogenic potential in contrast to normal CD34+ hematopoietic progenitor cells, suggesting a therapeutic window for MN1 targeting. In summary, our findings demonstrate that MN1 plays an essential role in MLL fusion leukemias and serve as a therapeutic target in MLL-rearranged acute myeloid leukemia.
Insights
Meningioma 1 (MN1) is crucial for MLL-rearranged acute myeloid leukemia development. Targeting MN1 inhibits leukemia cell growth and promotes differentiation, offering a potential therapeutic strategy.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- Mixed lineage leukemia (MLL/KMT2A) rearrangements (MLL-r) are common in acute myeloid leukemia (AML).
- The role of Meningioma 1 (MN1), a HOXA9 and MEIS1 co-factor, in MLL-r leukemia is not fully understood.
Purpose of the Study:
- To investigate the function of MN1 in MLL-r leukemia.
- To determine if MN1 is a viable therapeutic target in MLL-r AML.
Main Methods:
- CRISPR-Cas9 mediated deletion of MN1 in human and murine MLL-r leukemia models.
- Analysis of cell cycle, proliferation, apoptosis, and differentiation.
- Gene expression analysis and chromatin immunoprecipitation with sequencing (ChIP-seq).
- siRNA-mediated knockdown of MN1 in primary MLL-r leukemia cells.
Main Results:
- MN1 is essential for the in vivo leukemogenicity of MLL-r cells.
- Loss of MN1 inhibits proliferation, induces apoptosis, and promotes differentiation.
- MN1 maintains the active transcription of HOXA9, HOXA10, and their target genes (BCL2, MCL1, Survivin).
- Anti-MN1 siRNA treatment reduces the clonogenic potential of MLL-r cells but not normal hematopoietic progenitors.
Conclusions:
- MN1 plays a critical role in the pathogenesis of MLL-r leukemia.
- MN1 is a promising therapeutic target for MLL-rearranged acute myeloid leukemia.
More Related Videos
08:31Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
Published on: October 17, 2025
09:01Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
Related Concept Videos
Preparation of 1° Amines: Hofmann and Curtius Rearrangement Overview
Preparation of 1° Amines: Hofmann and Curtius Rearrangement Mechanism
[3,3] Sigmatropic Rearrangement of 1,5-Dienes: Cope Rearrangement
[3,3] Sigmatropic Rearrangement of Allyl Vinyl Ethers: Claisen Rearrangement
Preparation of Diols and Pinacol Rearrangement
The reaction begins with transferring a proton from the acid catalyst to one of the hydroxyl groups, producing an oxonium ion.
Lineage Commitment